WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...

(RTTNews) - Medical technologies firm Teleflex Inc. (TFX) announced Thursday that its UroLift System for treating benign prostatic hyperplasia or BPH has received regulatory clearance in China. The ...

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...

PLEASANTON, Calif., Aug. 20, 2020 /PRNewswire-PRWeb/ -- NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today ...

Teleflex (NYSE:TFX) reported new research from controlled and real-world studies of Prostatic Urethral Lift (PUL) procedure with its UroLift System to treat men with benign prostatic hyperplasia (BPH) ...

PLEASANTON, Calif., July 1, 2020 /PRNewswire-PRWeb/ -- NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today ...

UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...

UroLift is a minimally invasive treatment for Benign Prostatic Hyperplasia, a condition that causes an enlarged prostate in men. The procedure uses tiny implants to lift and hold the enlarged prostate ...

NeoTract, a wholly owned subsidiary of Teleflex Incorporated TFX focused on addressing unmet needs in the field of urology, today announced that Michael Brame, M.D., Carolina Urology Partners in ...

Physician brings non-surgical outpatient prostate procedure to McLaren Northern Michigan, providing quicker recovery times. Featured in the 2021 issue of MyNorth Medical Insider. When Bryan Shumaker, ...

Source: Getty Images Patients who underwent the minimally invasive procedure had a 36%, 50%, and 44% improvement in IPSS, quality of life, and peak flow rate, respectively, at 5 years. Prostatic ...

Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.